Physiologically-Based Pharmacokinetic Modeling to Predict the Clinical Efficacy of the Coadministration of Lopinavir and Ritonavir against SARS-CoV-2

Clicks: 221
ID: 116502
2020
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Lopinavir/ritonavir, originally developed for treating the human immunodeficiency virus (HIV), is currently undergoing clinical studies for treating the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although recent reports suggest that lopinavir exhibits in vitro efficacy against SAR …
Reference Key
a2020clinicalphysiologically-based Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Thakur A;Tan SPF;Chan JCY;;
Journal clinical pharmacology and therapeutics
Year 2020
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/32767755
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE pubmed abstract nih national institutes of health national library of medicine pmid:32767755 pmc7436510 doi:10.1002/cpt.2014 aarzoo thakur shawn pei feng tan james chun yip chan

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.